Jon H. Chung
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jon H. Chung has a total of 407 co-authors. Here are the top co-authors by number of shared publications:
- Russell W. Madison
Foundation Medicine, Cambridge, Massachusetts
57 shared publications - Brian Michael Alexander
Dana-Farber Cancer Institute, Boston, Massachusetts
56 shared publications Geoffrey R. Oxnard
54 shared publicationsVincent A. Miller
41 shared publications- Jeffrey S. Ross
Foundation Medicine, Cambridge, Massachusetts
37 shared publications Andrea Loehr
35 shared publications
Latest Publications
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from The Pan-Tumor Landscape of Targetable Kinase Fusions in Circulating Tumor DNA
Supplementary Data from The Pan-Tumor Landscape of Targetable Kinase Fusions in Circulating Tumor DNA
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from The Pan-Tumor Landscape of Targetable Kinase Fusions in Circulating Tumor DNA
Supplementary Data from The Pan-Tumor Landscape of Targetable Kinase Fusions in Circulating Tumor DNA
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Figure S8 from Genomic Analysis of Circulating Tumor DNA in 3,334 Patients with Advanced Prostate Cancer Identifies Targetable BRCA Alterations and AR Resistance Mechanisms
Variant allele fractions of DDR genes.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S8 from Genomic Analysis of Circulating Tumor DNA in 3,334 Patients with Advanced Prostate Cancer Identifies Targetable BRCA Alterations and AR Resistance Mechanisms
Variant allele fractions of DDR genes.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Table S1 from Genomic Analysis of Circulating Tumor DNA in 3,334 Patients with Advanced Prostate Cancer Identifies Targetable BRCA Alterations and AR Resistance Mechanisms
Regions of the genome baited in the two liquid biopsy assays, FoundationACT and FoundationOne Liquid.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Genomic Analysis of Circulating Tumor DNA in 3,334 Patients with Advanced Prostate Cancer Identifies Targetable BRCA Alterations and AR Resistance Mechanisms
Regions of the genome baited in the two liquid biopsy assays, FoundationACT and FoundationOne Liquid.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from The Pan-Tumor Landscape of Targetable Kinase Fusions in Circulating Tumor DNA
Supplementary Data from The Pan-Tumor Landscape of Targetable Kinase Fusions in Circulating Tumor DNA
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from The Pan-Tumor Landscape of Targetable Kinase Fusions in Circulating Tumor DNA
Supplementary Data from The Pan-Tumor Landscape of Targetable Kinase Fusions in Circulating Tumor DNA
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Table S5 from Genomic Analysis of Circulating Tumor DNA in 3,334 Patients with Advanced Prostate Cancer Identifies Targetable BRCA Alterations and AR Resistance Mechanisms
List of BRCA1/2 deleterious (red) and reversion (blue) mutations summarized in Fig 3C.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessTable S5 from Genomic Analysis of Circulating Tumor DNA in 3,334 Patients with Advanced Prostate Cancer Identifies Targetable BRCA Alterations and AR Resistance Mechanisms
List of BRCA1/2 deleterious (red) and reversion (blue) mutations summarized in Fig 3C.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from The Pan-Tumor Landscape of Targetable Kinase Fusions in Circulating Tumor DNA
Supplementary Data from The Pan-Tumor Landscape of Targetable Kinase Fusions in Circulating Tumor DNA
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from The Pan-Tumor Landscape of Targetable Kinase Fusions in Circulating Tumor DNA
Supplementary Data from The Pan-Tumor Landscape of Targetable Kinase Fusions in Circulating Tumor DNA
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Figure S3 from Genomic Analysis of Circulating Tumor DNA in 3,334 Patients with Advanced Prostate Cancer Identifies Targetable BRCA Alterations and AR Resistance Mechanisms
Alterations in PI3K, WNT, RAS and FGFR components in liquid biopsy.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Genomic Analysis of Circulating Tumor DNA in 3,334 Patients with Advanced Prostate Cancer Identifies Targetable BRCA Alterations and AR Resistance Mechanisms
Alterations in PI3K, WNT, RAS and FGFR components in liquid biopsy.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Figure S8 from Genomic Analysis of Circulating Tumor DNA in 3,334 Patients with Advanced Prostate Cancer Identifies Targetable BRCA Alterations and AR Resistance Mechanisms
Variant allele fractions of DDR genes.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S8 from Genomic Analysis of Circulating Tumor DNA in 3,334 Patients with Advanced Prostate Cancer Identifies Targetable BRCA Alterations and AR Resistance Mechanisms
Variant allele fractions of DDR genes.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Figure S4 from Genomic Analysis of Circulating Tumor DNA in 3,334 Patients with Advanced Prostate Cancer Identifies Targetable BRCA Alterations and AR Resistance Mechanisms
Genomic landscape of prostate cancer in liquid and tissue biopsy.
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Genomic Analysis of Circulating Tumor DNA in 3,334 Patients with Advanced Prostate Cancer Identifies Targetable BRCA Alterations and AR Resistance Mechanisms
Genomic landscape of prostate cancer in liquid and tissue biopsy.
- Open Access
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from The Pan-Tumor Landscape of Targetable Kinase Fusions in Circulating Tumor DNA
Supplementary Data from The Pan-Tumor Landscape of Targetable Kinase Fusions in Circulating Tumor DNA
- 31 March 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from The Pan-Tumor Landscape of Targetable Kinase Fusions in Circulating Tumor DNA
Supplementary Data from The Pan-Tumor Landscape of Targetable Kinase Fusions in Circulating Tumor DNA